@article{
author = "Filipić, Brankica and Rapajić-Moran, Ivana and Nikolić, Ines and Oljačić, Slavica and Mandić, Aljoša",
year = "2024",
abstract = "Human papillomaviruses (HPV) are the most common sexually transmitted pathogens
worldwide, leading to infections with a wide range of clinical manifestations: from benign
conditions to different types of cancer in women and men as well. Cervical cancer is highly
correlated with persistent high-risk-HPV (HR-HPV) infection, which is the key factor in
emergence of 99.99% of cervical cancer cases. The most effective way to prevent HPV-related
cancers is vaccination. There are three available prophylactic HPV vaccines: bivalent,
quadrivalent and nonavalent. The nonavalent vaccine is gradually replacing other HPV vaccines
in most countries and can be given from year 9, but it is commonly routinely implemented at the
age of 11 to 12. The World Health Organization has recognised cervical cancer as a global threat
and has announced the so-called 90-70-90 strategy to reduce and even eliminate cervical cancer.
This strategy implies that 90% of girls should be vaccinated by the age of 15, 70% of women
should be screened for cervical cancer, and 90% of women diagnosed with cervical disease should
receive adequate treatment. Although different treatment options are available: surgery, radiation
therapy, chemotherapy, and advanced target therapy using monoclonal antibodies, great efforts
are needed to achieve the goals set by the World Health Organization to eliminate cervical cancer., Humani papilomavirusi (HPV) su među najčešćim uzročnicima seksualno prenosivih patogena i mogu dovesti do različitih kliničkih manifestacija: od benignih stanja do različitih vrsta karcinoma kod žena, ali i muškaraca. Najčešći HPV-posredovan karcinom je karcinom grlića materice koji je u preko 99,99% slučajeva posledica infekcije. Najefikasniji način da se spreči razvoj perzistentne HR-HPV infekcije je vakcinacija. Dostupne su tri profilaktičke vakcine: dvovalentna, kvadrivalentna i devetovalentna. Devetovalentna vakcina pruža najširu zaštitu jer sadrži devet onkogenih HPV genotipova i postepeno zamenjuje ostale vakcine u svim zemljama. Sa vakcinacijom se može krenuti od 9. godine, ali se najčešće rutinski sprovodi kod dečaka i devojčica u uzrastu od 11 do 12 godina. Svetska zdravstvena organizacija je prepoznala karcinom grlića materice kao globalni problem i uvela takozvanu 90-70-90 strategiju u cilju smanjenja stope, pa čak i eliminacije karcinoma grlića materice. Ova strategija podrazumeva da 90% devojčica bude potpuno vakcinisano do 15. godine, 70% žena pristupi redovnom ginekološkom pregledu do 35. godine i ponovo do 45. godine i 90% žena sa promenama na grliću materice primi adekvatnu terapiju. Iako su dostupne različite terapije poput hirurškog tretmana, radioterapije, hemioterapije i ciljane terapije monoklonskim antitelima, i dalje su potrebni veliki napori da bi se dostigli ciljevi Svetske zdravstvene organizacije.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Human papillomaviruses and cervical cancer from the perspective of the World Health Organisation initiative for cervical cancer elimination, Humani papilomavirusi i karcinom grlića materice iz perspektive inicijative Svetske zdravstvene organizacije za eliminaciju karcinoma grlića materice",
volume = "74",
number = "1",
pages = "56-75",
doi = "10.5937/arhfarm74-48226"
}
